The false prophet has again misinformed readers. The research...

The false prophet has again misinformed readers. The research article he quoted in order to denigrate Noxopharm was largely irrelevant, or the following reasons:

1. Patients analysed by the research paper had an earlier stage of prostate cancer and anticipated survival of 2-5 years. Patients being treated in DARRT are very seriously ill, with anticipated survival of 3-6 MONTHS. Those who did not respond to DARRT therapy quickly died.

2. Patients in the research group received radiotherapy at a median rate of 60 Gy, which DARRT patients would not be able to tolerate. Noxopharm is using a dose level of 20 Gy because the lesions tend to be in sensitive areas such as the spine; or the rib cage over the heart.

The results achieved so far by Veyonda show great potential, in my opinion. No doubt the prophet will disagree, but his relentless and venomous campaign against Noxopharm has destroyed his credibility.